Category: Pharmaceuticals
Will Biosimilars Trigger The Next Wave Of Blockbuster Biologics?
Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure Did you know that 46 new drugs and biological products were approved by the FDA in 2017 ... Read More
Psoriasis Treatments to Become Cheaper as Biosimilars Compete in $5 Billion U.S. Psoriasis Drugs Market – New Study by iData Research
Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure A new study by iData Research estimates that there are nearly 150,000 new cases of pso... Read More
Will Humira Competitors Take Over the Immunology Drugs Market?
In a new series of reports by iData Research, it was revealed that in 2017, the U.S. immunology market was valued at over $34 billion. A major portion of this revenue came from the biologic Humira, wh... Read More
Humira, Enbrel, Remicade Immunology Drugs Face Stiff Competition in the US from New Biosimilars Due to Patent Expiry
Overall, the U.S. immunology drug market is projected to exceed an estimated $38 billion by 2023 due to the entry of new biosimilars and JAK inhibitors into the market.... Read More
Biosimilars – A Game Changer in the Immunology Rheumatoid Arthritis Market
Biosimilars are, as the name would suggest, highly similar and are a more affordable alternative to biologics that is poised to influence the current dynamics of the immunology market. ... Read More
AbbVie, Johnson & Johnson Lead US Immunology Drug Market Due to High Cost of Biologic Treatments
The U.S. immunology drug market is expected to grow to $68 billion by 2023 due to the entry of new biosimilars and JAK inhibitors.... Read More
Sandoz Proposed Biosimilar Rituximab Accepted for Review by the FDA
Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our biosimilar rituximab matches the reference medicine in terms of safety, efficacy and quality... Read More
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen Allowing Commercialization Of AMGEVITA™
Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates... Read More
Samsung, Biogen version of AbbVie’s Humira approved in Europe
The new drug, Imraldi, marks the third European Commission approval for “biosimilar” versions from the joint venture, Samsung Bioepis, of drugs in a class known as TNF inhibitors.... Read More- 2 of 3
- « Previous
- 1
- 2
- 3
- Next »
